Tethering of Shattered Chromosomal Fragments Paves Way for New Cancer Therapies
|
UC San Diego scientists have discovered that shattered chromosomal fragments are tethered together during cell division before being rearranged; destroying the tether may help prevent cancerous mutations. Read More»
|
|
|
Now Hiring – Moores Research and Grant Development Manager
|
The Research and Grant Development Manager is responsible for short- and long-term strategic program planning to advance the goals and mission of Moores Cancer Center. Responsibilities involve the scientific, regulatory, administrative, and budgetary dimensions germane to collaborative cancer research. Apply Here»
|
Moores Office of Translational Science Speed Networking Initiative
|
Unleash the power of collaboration with the Speed Networking Initiative, which fosters collaboration and facilitates the advancement of translational research. If you are seeking collaborators on your project and require assistance, then complete the form provided below by July 30, 2023. Moores OTS will facilitate the process of connecting you with up to 10 investigators who may be potential collaborators. Complete Form»
|
|
|
July 25, 2023 | 3:00 p.m. ET
Zoom
|
August 1 – August 4, 2023
|
| |
NCI Cancer Prevention Fellowship Program
|
Applications for this postdoctoral fellowship program are open through August 1, 2023.
|
|
Applications for KL2 Mentored Career Development Award Now Open!
|
The ACTRI KL2 award is a mentored career development award that provides up to $120K toward salary, plus benefits, along with $25K per year in research funds. Successful applicants will receive up to 3 years of support. Applications for this program are open through August 15, 2023.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
This award is for the next generation of creative thinkers with "high-risk/high-reward" ideas that have the potential to improve our understanding of and/or approaches to the prevention, diagnosis, and treatment of cancer. This award will fund early career researchers who have an innovative idea yet lack sufficient preliminary data to obtain traditional funding.
Deadline: Thursday, July 6, 2023
|
This NOSI will enable current NCI grant awardees or cooperative agreement program participants to collaborate with NCI CAP-IT Specialized Centers to support CAP-IT Program research. Collaborations should be proposed by investigators who are not currently CAP-IT Center investigators and whose research scope, interests, and activities, as specified in the parent awards, serve CAP-IT Program research objectives. Potential applicants are encouraged to contact the NCI Program Director to discuss the planned collaboration and application.
Deadline: Thursday, July 6, 2023
|
The goal of these Research Grants and Fellowships Programs is to identify and provide funding for innovative projects that exhibit the potential to make substantial contributions to cancer prevention and early detection. The Prevent Cancer Foundation defines cancer prevention as the “reduction of cancer incidence through research, education, and early detection.” Both Research Grants and Fellowships Programs will be awarded for 2 years at $50,000 per year, for a total of $100,000.
Deadline: Tuesday, July 11, 2023
|
This RFA will fund up to $500,000 for a research proposal featuring novel technology or new approaches for target discovery or treatment in gastroesophageal cancer. Grantees will gain access to a supply of gastroesophageal cell lines, patient-derived organoids, and mouse models to facilitate research projects.
Deadline: Tuesday, August 1, 2023
|
This retention-focused, institutionally-supported program is intended to support under-represented minority faculty members in submitting successful resubmissions of NIH K or R (or equivalent) grant applications. The goal of the SUSTAIN program is to increase the likelihood of successful proposal resubmission by providing protected time, grant writing training, and linkage to didactic, mentorship, and other resources, which are customized to the applicant. The SUSTAIN program provides 1 to 2 years of support at 50% of full-time salary (up to $60,000), which must be matched by the department and confirmed in a letter from the candidate’s Department Chair. The combined effort must enable a total of at least 75% research effort.
Deadline: Friday, September 1, 2023
|
|
|
Molecular Cancer
Kun-Liang Guan (Cancer Biology and Signaling)
|
Cell Metabolism
Alexandra C. Newton (Cancer Biology and Signaling), Tatiana Kisseleva (Cancer Biology and Signaling), Alan R. Saltiel, and Michael Karin (Solid Tumor Therapeutics)
| Journal of Hepatology
Rohit Loomba (Cancer Control Program)
|
|
|
R3767-ONC-2011: A Phase III Trial of Fianlimab (REGN3767, antiLAG3) Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
|
PI: Gregory Daniels
NCT: NCT05352672
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|
